Scholar Rock Holding Corporation (NASDAQ:SRRK) Given Average Recommendation of "Buy" by Brokerages

Key Points

• Scholar Rock Holding has a consensus analyst rating of “Buy” from 17 covering analysts, with an average 12-month price target of $56.00. Most analysts are bullish, though one sell rating remains.
• Recent insider activity included stock sales by directors Michael Gilman and Kristina Burow, both tied to tax withholding obligations from vesting equity awards. Insiders sold 17,149 shares worth about $923,108 over the last 90 days.
• The stock fell 3.7% to $47.67, and the company most recently reported a quarterly EPS of -$0.83, slightly worse than estimates. Scholar Rock remains a clinical-stage biotech focused on its lead program SRK-015 for spinal muscular atrophy.

Scholar Rock Holding Corporation (NASDAQ:SRRK - Get Free Report) has been given a consensus rating of "Buy" by the seventeen analysts that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, twelve have assigned a buy rating and four have given a strong buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $56.00.

SRRK has been the topic of a number of research reports. Barclays boosted their price objective on Scholar Rock from $53.00 to $55.00 and gave the stock an "overweight" rating in a research note on Friday, May 8th. Wedbush reiterated an "outperform" rating and set a $58.00 price objective on shares of Scholar Rock in a research report on Tuesday, July 21st. Canaccord Genuity Group began coverage on Scholar Rock in a research note on Monday, April 20th. They issued a "buy" rating and a $62.00 price target on the stock. HC Wainwright boosted their price target on shares of Scholar Rock from $58.00 to $65.00 and gave the company a "buy" rating in a report on Friday, May 8th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Scholar Rock in a research note on Friday, July 17th.

Insider Buying and Selling

In other news, Director Michael Gilman sold 2,544 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $53.87, for a total value of $137,045.28. Following the completion of the sale, the director directly owned 59,511 shares of the company's stock, valued at $3,205,857.57. This represents a 4.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kristina Burow sold 3,053 shares of the firm's stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $53.74, for a total transaction of $164,068.22. Following the sale, the director owned 114,657 shares of the company's stock, valued at approximately $6,161,667.18. This represents a 2.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 17,149 shares of company stock worth $923,108 over the last ninety days. 10.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Scholar Rock

A number of institutional investors have recently modified their holdings of SRRK. AQR Capital Management LLC grew its holdings in shares of Scholar Rock by 609.3% during the 1st quarter. AQR Capital Management LLC now owns 57,294 shares of the company's stock valued at $1,842,000 after acquiring an additional 49,217 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Scholar Rock by 12.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,046 shares of the company's stock worth $1,709,000 after acquiring an additional 5,831 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Scholar Rock by 37.4% during the first quarter. Millennium Management LLC now owns 200,255 shares of the company's stock worth $6,438,000 after acquiring an additional 54,555 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Scholar Rock by 25.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company's stock valued at $5,460,000 after purchasing an additional 34,594 shares during the last quarter. Finally, Strs Ohio acquired a new stake in Scholar Rock during the first quarter valued at $77,000. Institutional investors and hedge funds own 91.08% of the company's stock.

Scholar Rock Trading Down 3.7%

Shares of SRRK stock opened at $47.67 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 8.64 and a current ratio of 8.64. Scholar Rock has a 1 year low of $27.07 and a 1 year high of $58.49. The stock has a fifty day moving average of $50.02 and a two-hundred day moving average of $47.47. The firm has a market capitalization of $5.71 billion, a PE ratio of -13.28 and a beta of 0.67.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.01). During the same period in the prior year, the company earned ($0.67) earnings per share. As a group, research analysts expect that Scholar Rock will post -3.23 EPS for the current year.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company's research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock's approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company's lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.